<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17962" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Atrial Fibrillation</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nesheiwat</surname>
            <given-names>Zeid</given-names>
          </name>
          <aff>The University of Toledo</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goyal</surname>
            <given-names>Amandeep</given-names>
          </name>
          <aff>University of Kansas Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jagtap</surname>
            <given-names>Mandar</given-names>
          </name>
          <aff>Magnolia Regional Health Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zeid Nesheiwat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amandeep Goyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mandar Jagtap declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17962.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Atrial fibrillation is the most common type of cardiac arrhythmia. It is the leading cardiac cause of stroke. Risk factors for atrial fibrillation include advanced age, high blood pressure, underlying heart and lung disease, congenital heart disease, and increased alcohol consumption. Although atrial fibrillation may be a permanent disease, various treatments, and risk modifying strategies have been developed to help reduce the risk of stroke in patients that remain in atrial fibrillation. Treatments include anticoagulation, rate control medication, rhythm control medication, cardioversion, ablation, and other interventional cardiac procedures. This activity describes the evaluation, diagnosis, and management of atrial fibrillation and highlights the role of team-based interprofessional care for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of atrial fibrillation.</p></list-item><list-item><p>Outline the pathophysiology of atrial fibrillation.</p></list-item><list-item><p>Summarize the treatment and management options available for atrial fibrillation.</p></list-item><list-item><p>Explain the interprofessional team strategies for improving care coordination and communication regarding the management of patients with atrial fibrillation.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17962&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17962">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17962.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Atrial fibrillation is the most common type of cardiac arrhythmia. It is due to abnormal electrical activity within the atria of the heart, causing them to fibrillate. It is characterized as a tachyarrhythmia, which means that the heart rate is often fast.&#x000a0;This arrhythmia may be paroxysmal (less than seven days) or persistent (more than seven days). Due to its rhythm irregularity, blood flow through the heart becomes turbulent and has a high chance of forming a thrombus (blood clot), which can ultimately dislodge and cause a stroke. Atrial fibrillation is the leading cardiac cause of stroke.&#x000a0;Risk factors for atrial fibrillation include advanced age, high blood pressure, underlying heart and lung disease, congenital heart disease, and increased alcohol consumption. Symptoms vary from asymptomatic to symptoms such as chest pain, palpitations, fast heart rate, shortness of breath, nausea, dizziness, diaphoresis (severe sweating), and generalized fatigue. Although atrial fibrillation may be a permanent disease, various treatments, and risk modifying strategies have been developed to help reduce the risk of stroke in patients that remain in atrial fibrillation. Treatments include anticoagulation, rate control medication, rhythm control medication, cardioversion, ablation, and other interventional cardiac procedures.&#x000a0;<xref ref-type="bibr" rid="article-17962.r1">[1]</xref><xref ref-type="bibr" rid="article-17962.r2">[2]</xref><xref ref-type="bibr" rid="article-17962.r3">[3]</xref></p>
      </sec>
      <sec id="article-17962.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are many causes of atrial fibrillation (AF), but it shares a strong association with other cardiovascular diseases. The commonly encountered causes include:</p>
        <list list-type="order">
          <list-item>
            <p>Advanced age</p>
          </list-item>
          <list-item>
            <p>Congenital heart disease</p>
          </list-item>
          <list-item>
            <p>Underlying heart disease - valvular disease, coronary artery disease, structural heart disease, atrial ischemia</p>
          </list-item>
          <list-item>
            <p>Increased alcohol consumption</p>
          </list-item>
          <list-item>
            <p>Hypertension - systemic or pulmonary</p>
          </list-item>
          <list-item>
            <p>Endocrine disorders - diabetes, pheochromocytoma, and hyperthyroidism</p>
          </list-item>
          <list-item>
            <p>Genetic factors</p>
          </list-item>
          <list-item>
            <p>Neurologic disorders - subarachnoid hemorrhage or stroke</p>
          </list-item>
          <list-item>
            <p>Hemodynamic stress - mitral or tricuspid valve disease, left ventricular dysfunction, pulmonary embolism</p>
          </list-item>
          <list-item>
            <p>Obstructive sleep apnea</p>
          </list-item>
          <list-item>
            <p>Inflammation - myocarditis and pericarditis</p>
          </list-item>
        </list>
        <p>Any&#x000a0;condition&#x000a0;that leads to inflammation, stress, damage, or ischemia affecting the&#x000a0;anatomy&#x000a0;of the heart can&#x000a0;result in the development of atrial fibrillation. In some cases, the cause is iatrogenic.<xref ref-type="bibr" rid="article-17962.r4">[4]</xref></p>
        <p>Atrial fibrillation is&#x000a0;referred to as recurrent when a patient has two or more episodes. The three patterns of atrial fibrillation include:</p>
        <p>Paroxysmal AF: If recurrent AF reverts spontaneously, it is called paroxysmal AF. Here, the episodes terminate spontaneously within seven days. In younger patients, paroxysmal AF has been commonly found to be secondary to electrically active foci within the pulmonary veins. Elimination of these foci is found to be effective in treating this type of AF since it eliminates the trigger for such episodes.</p>
        <p>Persistent AF: If recurrent AF persists, needing either pharmacological or electrical cardioversion, it is called&#x000a0;persistent AF. In this case, the episodes last more than seven days, and if it is associated with a rapid and uncontrolled ventricular rate, it may lead to electrical remodeling in the cardiac myocytes causing dilated cardiomyopathy. This type of AF may present as the first episode or as a result of recurrent episodes of paroxysmal AF.&#x000a0;</p>
        <p>Long-standing persistent AF: AF that has been present for more than 12 months, either due to the failure of initiation of pharmacological intervention or failure of cardioversion.</p>
        <p>Permanent AF: It is the type where a decision has been made to abort all therapies because the rhythm is unresponsive.</p>
      </sec>
      <sec id="article-17962.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Atrial fibrillation is the most commonly encountered cardiac rhythm disorder. The prevalence of atrial fibrillation has been increasing worldwide. It is known that&#x000a0;the prevalence of atrial fibrillation generally&#x000a0;increases with age. It has been estimated that the number of individuals with atrial fibrillation will double or triple by the year 2050. Although the worldwide prevalence of atrial fibrillation is approximately 1%, it is found in approximately 9% of individuals over the age of 75. At the age of&#x000a0;80, the lifetime risk of developing atrial fibrillation jumps to 22%. In addition, atrial fibrillation has more commonly been associated with males and is seen more often in whites as compared to blacks.<xref ref-type="bibr" rid="article-17962.r5">[5]</xref><xref ref-type="bibr" rid="article-17962.r6">[6]</xref></p>
      </sec>
      <sec id="article-17962.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>There are a wide variety of pathophysiological mechanisms that play a role in the development of atrial fibrillation (AF); however, it is cardiac remodeling that accounts for&#x000a0;most of them. Cardiac remodeling, particularly of atria, results in structural and electrical changes that eventually become the cause of deranged rhythm in AF. Structural remodeling is caused by the changes in myocytes and the extracellular matrix, and fibrous tissue deposition also plays a major role in some etiologies. On the other hand, tachycardia and shortening of the refractory period lead to electrical remodeling.</p>
        <p>Most commonly, hypertension, structural, valvular, and ischemic heart disease illicit the paroxysmal and persistent forms of atrial fibrillation, but the underlying pathophysiology is not well understood. Some research has shown evidence of genetic causes of atrial fibrillation involving chromosome 10 (10q22-q24) that consists of a mutation in the gene alpha-subunit of the cardiac Ik5, which is responsible for pore formation. This is a gain of function mutation, allowing for more pores, increasing the activity within the ion channels of the heart, and thus affecting the stability of the membrane and reducing its refractory time.&#x000a0;<xref ref-type="bibr" rid="article-17962.r1">[1]</xref>&#x000a0;</p>
        <p>Most cases of atrial fibrillation are non-genetic and relate to underlying cardiovascular disease. Typically, an initiating trigger excites an ectopic focus in the atria, most commonly around the area of the pulmonary veins, and allows for an unsynchronized firing of electrical impulses leading to fibrillation of the atria. These impulses are irregular, and pulse rates can vary tremendously. Overall, atrial fibrillation leads to a turbulent and abnormal flow of blood through the heart chamber, decreasing the heart's effectiveness in pumping blood while increasing the likelihood of thrombus formation within the atria, most commonly the left atrial appendage.</p>
        <p>Triggers for AF include:</p>
        <list list-type="order">
          <list-item>
            <p>Atrial ischemia</p>
          </list-item>
          <list-item>
            <p>Inflammation</p>
          </list-item>
          <list-item>
            <p>Alcohol and illicit drug use</p>
          </list-item>
          <list-item>
            <p>Hemodynamic stress</p>
          </list-item>
          <list-item>
            <p>Neurological and endocrine disorders</p>
          </list-item>
          <list-item>
            <p>Advanced age</p>
          </list-item>
          <list-item>
            <p>Genetic factors</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17962.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>History and physical exam are crucial for diagnosing and risk stratifying patients with atrial fibrillation. The presentation of AF can&#x000a0;range from asymptomatic to devastating complications such as cardiogenic shock and ischemic stroke. A complete history should focus on symptoms such as palpitations, chest pain, shortness of breath, increased lower extremity swelling, dyspnea on exertion, and dizziness. In addition, history is imperative in identifying risk factors such as hypertension, history of valvular, structural, or ischemic heart disease, obstructive sleep apnea, obesity hypoventilation syndrome, smoking, alcohol intake, illicit drug use, history of rheumatic fever/heart disease, history of pericarditis, and hyperlipidemia. Initial evaluation of any patient presenting with features of AF should include the assessment for hemodynamic instability. Assessment of patients with existing AF includes questions regarding:</p>
        <list list-type="order">
          <list-item>
            <p>Duration and frequency of symptoms</p>
          </list-item>
          <list-item>
            <p>History of triggers</p>
          </list-item>
          <list-item>
            <p>Previously successful modes of termination</p>
          </list-item>
          <list-item>
            <p>The use of anti-arrhythmic drugs</p>
          </list-item>
          <list-item>
            <p>Antecedent cardiac diseases</p>
          </list-item>
        </list>
        <p>A physical exam should always begin with the assessment of airway breathing and circulation as it is going to affect the decision-making regarding management. On general physical examination, patients may be tachycardic with an irregularly irregular pulse. The heart rate usually ranges from 110/min to 140/min.&#x000a0;Extremities should be evaluated for edema, peripheral pulses in both upper and lower extremities, and integumentary signs of peripheral vascular disease (PVD), such as hair loss and skin breakdown.</p>
        <p>The physical exam should focus on identifying the cause of AF. For instance, examining the neck of the patient may give some clues regarding carotid artery disease or thyroid problems. The pulmonary examination may reveal signs of heart failure in the form of rales, and the presence of wheezing may indicate antecedent pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD). A cardiovascular exam should consist of careful auscultation of all four cardiac posts and palpation of apical impulse, as this would be crucial in diagnosing an underlying valvular pathology. An abdominal exam should consist of palpating the aorta and listening for abdominal bruits. Moreover, hepatomegaly and abdominal distension may indicate heart failure. Subsequently, a careful examination of the central and peripheral nervous system may reveal signs of transient ischemic attack or cerebrovascular accident.</p>
      </sec>
      <sec id="article-17962.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Aside from a detailed history and examination, the ECG is critical in making the diagnosis of atrial fibrillation. On ECG, atrial fibrillation presents with the typical narrow complex "irregularly irregular" pattern&#x000a0;with no distinguishable p-waves. Fibrillatory waves may be seen, or they may be absent. The ventricular rate usually ranges between 80 and 180/min.</p>
        <p>Laboratory work is required to evaluate for the causes of atrial fibrillation, for example, a complete blood count (CBC) for infection, basic metabolic panel (BMP) for electrolyte abnormalities, thyroid function tests to evaluate for hyperthyroidism, and a chest x-ray to evaluate the thorax for any abnormality.</p>
        <p>Several cardiac diseases are associated with AF; therefore, it is essential to send cardiac biomarkers and B-type natriuretic peptide (BNP) to preclude the underlying cardiac disorder. Interventions such as cardiac catheterization may also be needed in certain cases if the history and physical findings are suggestive.</p>
        <p>It is imperative to evaluate the patient for pulmonary embolism (with the d-dimers test or spiral CT scan) because the right heart strain can lead to atrial malfunctioning and atrial fibrillation. The patient should be risk-stratified for pulmonary embolism using the PERC and/or Wells criteria.&#x000a0;In addition, a transesophageal echocardiogram should be done for these patients to evaluate for atrial thrombus secondary to atrial fibrillation and heart structure. It is important to note that a transesophageal echocardiogram (TEE) should always be done prior to cardioversion in these patients to minimize the risk of stroke.<xref ref-type="bibr" rid="article-17962.r7">[7]</xref><xref ref-type="bibr" rid="article-17962.r8">[8]</xref></p>
      </sec>
      <sec id="article-17962.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of atrial fibrillation in the acute setting depends on hemodynamic stability and risk stratification. In cases where the patient is hemodynamically unstable, it is recommended to carry out immediate cardioversion with anticoagulant therapy. Although TEE is recommended before any cardioversion; however, if the patient is hemodynamically unstable due to a rapid ventricular response, cardioversion may be indicated without prior TEE. If there is evidence of rapid ventricular response, a beta-blocker or calcium-channel blocker should be commenced for rate control. These&#x000a0;options can be used in the intravenous (IV) form for rapid response. Usually, a bolus is administered to the patient and then started on a drip if symptoms do not resolve. Digoxin can be considered for rate control but is not advised as a first-line agent&#x000a0;pertaining to its adverse effects and tolerance. Amiodarone can also be&#x000a0;given&#x000a0;as a rhythm control agent but is also not a first-line&#x000a0;option in the acute setting. In any case, if the decision to start amiodarone is made,&#x000a0;cardiology should be consulted&#x000a0;before its administration.</p>
        <p>In&#x000a0;the case of preexisting atrial fibrillation, the patient should be risk-stratified using the CHADs-2-Vasc score, which is&#x000a0;helpful in estimating the risk of stroke per year. If the patient receives a 0 score,&#x000a0;it is considered "low-risk," and anticoagulation is not recommended in such cases. If the patient receives a score of 1,&#x000a0;it falls in&#x000a0;the "low-moderate" risk category; the providers should consider anticoagulant or antiplatelet therapy. If the patient receives a score of greater than 2, they are in the "moderate-high" risk category, and anticoagulation therapy is indicated.<xref ref-type="bibr" rid="article-17962.r2">[2]</xref>&#x000a0;Rate or rhythm control should also be given to the patient; medications such as beta-blockers, calcium channel blockers, amiodarone, dronedarone, and digoxin are available options. HAS-BLED is also a scoring system that can be used to assess the risk of bleeding for the patient. This is a good indicator of bleeding risk for a patient that is being considered for anticoagulation.</p>
        <p>Non-pharmacological therapy includes ablation therapy. Pacemaker placement is considered in severe cases resulting in heart failure in atrial fibrillation.<xref ref-type="bibr" rid="article-17962.r9">[9]</xref><xref ref-type="bibr" rid="article-17962.r10">[10]</xref><xref ref-type="bibr" rid="article-17962.r11">[11]</xref></p>
        <p>
<bold>Current guidelines</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>In patients with AF and elevated CHA2DS2-VASc score of 2 or more, oral anticoagulation is recommended.</p>
          </list-item>
          <list-item>
            <p>Females with the absence of AF risk factors and males with CHA2DS2-VASc of 1 or 0 have a low stroke risk.</p>
          </list-item>
          <list-item>
            <p>Non-vitamin K oral anticoagulants (apixaban, dabigatran, edoxaban, and rivaroxaban) are recommended over warfarin, except for patients with moderate to severe MS with a mechanical heart valve in place.</p>
          </list-item>
          <list-item>
            <p>In all patients with AF, the CHA2DS2-VASc score is recommended to assess stroke risk.</p>
          </list-item>
          <list-item>
            <p>Obtain renal and liver function before initiating non-vitamin K oral anticoagulants.</p>
          </list-item>
          <list-item>
            <p>Aspirin is not recommended in patients with low CHA2DS2-VASc scores.</p>
          </list-item>
          <list-item>
            <p>Idarucizumab is recommended for dabigatran reversal if there is an urgent procedure or bleeding. Andexanet alfa is recommended for the reversal of rivaroxaban and apixaban associated bleeding.</p>
          </list-item>
          <list-item>
            <p>Percutaneous left atrial appendage occlusion is recommended in AF patients with a risk of stroke who have contraindications to long term anticoagulation.</p>
          </list-item>
          <list-item>
            <p>If the duration of AF is more than 48 hours or if the time is unknown, start anticoagulation and maintain INR between 2-3 or commence a factor Xa inhibitor for at least three weeks before and at least four weeks after cardioversion.</p>
          </list-item>
          <list-item>
            <p>Catheter ablation is an option in patients with a low ejection fraction.</p>
          </list-item>
          <list-item>
            <p>Recommend weight loss in obese patients with AF.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17962.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>History and examination play a crucial role in distinguishing various causes of atrial fibrillation. Different presentations on electrocardiography are a cornerstone in establishing the etiology of AF.</p>
        <p>Differential diagnoses include:</p>
        <list list-type="order">
          <list-item>
            <p>Atrial flutter - However, atrial fibrillation has a distinctive irregularly irregular rhythm with absent P-waves, whereas atrial flutter has a regularly irregular rhythm with absent P-waves.</p>
          </list-item>
          <list-item>
            <p>Atrial tachycardia</p>
          </list-item>
          <list-item>
            <p>Multifocal atrial tachycardia</p>
          </list-item>
          <list-item>
            <p>Wolf-Parkinson-White syndrome</p>
          </list-item>
          <list-item>
            <p>Atrioventricular nodal reentry tachycardia.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17962.s10" sec-type="Staging">
        <title>Staging</title>
        <p>
<bold>Classification of atrial fibrillation</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Paroxysmal AF is when the episodes terminate spontaneously or with treatment within 7 days. But they may recur with an unpredictable frequency</p>
          </list-item>
          <list-item>
            <p>Persistent AF is when the AF is continuous and lasts for more than 7 days, and fails to terminate&#x000a0;spontaneously.</p>
          </list-item>
          <list-item>
            <p>Long-standing&#x000a0;AF is when&#x000a0;the continuous AF&#x000a0;lasts more than 12 months</p>
          </list-item>
          <list-item>
            <p>Permanent is when AF is accepted, and no further treatments are attempted to restore or maintain normal sinus rhythm</p>
          </list-item>
          <list-item>
            <p>Non-valvular AF occurs in the absence of rheumatic mitral valve disease, mitral valve repair, or a prosthetic heart valve.</p>
          </list-item>
        </list>
        <p>
<bold>CHA2DS2-VASc score</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Heart failure - 1</p>
          </list-item>
          <list-item>
            <p>Hypertension - 1</p>
          </list-item>
          <list-item>
            <p>Age more than 75 - 2</p>
          </list-item>
          <list-item>
            <p>Diabetes - 1</p>
          </list-item>
          <list-item>
            <p>Stroke, transient ischemic attack- 2</p>
          </list-item>
          <list-item>
            <p>Peripheral vascular disease - 1</p>
          </list-item>
          <list-item>
            <p>Age 65-74 - 1</p>
          </list-item>
          <list-item>
            <p>Female sex - 1</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17962.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>AF is associated with a high risk of thromboembolism and death. Evidence shows that rhythm control does not offer a survival advantage over rate control. Patients with AF have multiple admissions and anticoagulation-related complications over their lifetime. The risk of stroke is ever-present, and the overall quality of life of patients is poor.&#x000a0; Finally, the management of atrial fibrillation is prohibitively expensive, with most of the financial burden borne by the patient.</p>
      </sec>
      <sec id="article-17962.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The major side effect of atrial fibrillation is a stroke. Cerebral vascular accidents (CVA) can lead to severe morbidity and mortality. CVA risk can be reduced significantly by anticoagulation with adjunct rate/rhythm therapy. Other&#x000a0;complications include heart&#x000a0;disease and heart failure secondary.</p>
      </sec>
      <sec id="article-17962.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Atrial fibrillation is a commonly encountered disease that affects many individuals. Advancing age is associated with increased prevalence, with the most catastrophic complication being an acute hemorrhagic stroke. Due to the irregularity of the atria, blood flow through this chamber becomes turbulent, leading to thrombus formation. The most common site for this embolus is the atrial appendage. The thrombus can dislodge and embolize to the brain and other parts of the body. It is essential for the patient to seek medical care immediately if they are experiencing chest pain, palpitations, shortness of breath, severe sweating, or extreme dizziness.</p>
      </sec>
      <sec id="article-17962.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Atrial fibrillation is a chronic disorder that can seriously affect the quality of life and costs healthcare billions of dollars each year. Each year, thousands of patients develop stroke and other embolic phenomena, leading to significant disability. The disorder is best managed by an interprofessional team to improve outcomes.</p>
        <p>A nurse should be dedicated to monitoring the anticoagulation profile and ensuring the INR is within the therapeutic range. In addition, the nurse should immediately communicate with the team if there are signs of a stroke or other embolic phenomenon. The nurse has to educate the patient on medication compliance for hypertension and coronary disease and ensure follow-up at regular intervals. Finally, the patient should be educated about the symptoms of a stroke and when to return to the emergency department.<xref ref-type="bibr" rid="article-17962.r12">[12]</xref></p>
        <p>The pharmacist should inform the patient of the different anticoagulants, their benefits, and the adverse risk profile. Besides, the pharmacist should also ensure that the patient is compliant with the medications.</p>
        <p>While cardiologists treat the disorder, the role of the pharmacist is critical. Many of these patients are on multiple medications, including antiarrhythmic agents and anticoagulants. In addition, there is some&#x000a0;evidence indicating that the use of angiotensin receptor blockers and statins may lower the frequency of atrial fibrillation and increase the probability of successful cardioversion. Thus, the pharmacist has to make sure that the patient's medication doses are therapeutic, there are no drug interactions, and that the patient has therapeutic anticoagulation to prevent a stroke.<xref ref-type="bibr" rid="article-17962.r12">[12]</xref><xref ref-type="bibr" rid="article-17962.r13">[13]</xref><xref ref-type="bibr" rid="article-17962.r14">[14]</xref>&#x000a0;[Level 5]</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Atrial fibrillation prevalence has been on the rise. The risk of stroke is 5-times higher in a patient with known atrial fibrillation compared to the general&#x000a0;public. It is estimated that 19.6% of patients over the age of 65 will have apparent atrial fibrillation by 2030. The most feared side effect of atrial fibrillation is an acute stroke, which can lead to severe morbidity and mortality. It has been shown that 60% of strokes secondary to atrial fibrillation can be avoided with the use of anticoagulants. Using the CHADs-2-VASc score to evaluate patients with atrial fibrillation is a helpful guide for the management of these patients with the ultimate&#x000a0;goal of preventing stroke. Proper risk factor stratification and medical/surgical therapy can decrease the risk of stroke and heart failure significantly.<xref ref-type="bibr" rid="article-17962.r3">[3]</xref></p>
      </sec>
      <sec id="article-17962.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17962&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17962">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/atrial-fibrillation-a-fib/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17962">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17962/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17962">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17962.s16">
        <fig id="article-17962.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Atrial Fibrillation ECG example Contributed by Tammy J. Toney-Butler, RN, CEN, TCRN, CPEN</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="EKG__AFIB__png" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-17962.s17">
        <fig id="article-17962.image.f2" position="float" orientation="portrait">
          <caption>
            <p>atrial fibrillation Contributed by S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="afib" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-17962.s18">
        <fig id="article-17962.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Atrial fibrillation Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="atrialfibri" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-17962.s19">
        <fig id="article-17962.image.f4" position="float" orientation="portrait">
          <caption>
            <p>ECG for an Atrial fibrillation's case. AMBOSS library. It's a studying tool, I didn't take permission for it.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="big_59948e7953cf2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17962.s20">
        <title>References</title>
        <ref id="article-17962.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markides</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schilling</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment.</article-title>
            <source>Heart</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>89</volume>
            <issue>8</issue>
            <fpage>939</fpage>
            <page-range>939-43</page-range>
            <pub-id pub-id-type="pmid">12860883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Houmsse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ishola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tyler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Houmsse</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The current approach of atrial fibrillation management.</article-title>
            <source>Avicenna J Med</source>
            <year>2016</year>
            <season>Jan-Mar</season>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-16</page-range>
            <pub-id pub-id-type="pmid">26955600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McManus</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Rienstra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>An update on the prognosis of patients with atrial fibrillation.</article-title>
            <source>Circulation</source>
            <year>2012</year>
            <month>Sep</month>
            <day>04</day>
            <volume>126</volume>
            <issue>10</issue>
            <fpage>e143</fpage>
            <page-range>e143-6</page-range>
            <pub-id pub-id-type="pmid">22949543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohanty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gianni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Natale</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Gender specific considerations in atrial fibrillation treatment: a review.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>365</fpage>
            <page-range>365-374</page-range>
            <pub-id pub-id-type="pmid">29424249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>SAE</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Established and novel risk factors for atrial fibrillation in women compared with men.</article-title>
            <source>Heart</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>226</fpage>
            <page-range>226-234</page-range>
            <pub-id pub-id-type="pmid">30158135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Choe</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy: A nationwide population-based study.</article-title>
            <source>Int J Cardiol</source>
            <year>2018</year>
            <month>Dec</month>
            <day>15</day>
            <volume>273</volume>
            <fpage>130</fpage>
            <page-range>130-135</page-range>
            <pub-id pub-id-type="pmid">30150122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Porot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vernay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Buffet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fichot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guenancia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pommier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mouhat</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lorgis</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Incidence, Predictive Factors, and Prognostic Impact of Silent Atrial Fibrillation After Transcatheter Aortic Valve Implantation.</article-title>
            <source>Am J Cardiol</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>122</volume>
            <issue>3</issue>
            <fpage>446</fpage>
            <page-range>446-454</page-range>
            <pub-id pub-id-type="pmid">30201110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarride</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Blackhouse</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gladstone</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ivers</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Dolovich</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thornton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakamya</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramasundarahettige</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Frydrych</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Henein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Congdon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Birtwhistle</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Healey</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective in Patients 65 Years and Older?</article-title>
            <source>Can J Cardiol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>11</issue>
            <fpage>1522</fpage>
            <page-range>1522-1525</page-range>
            <pub-id pub-id-type="pmid">30144961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karnad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pannelay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boshnakova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lovell</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Stroke prevention in Europe: how are 11 European countries progressing toward the European Society of Cardiology (ESC) recommendations?</article-title>
            <source>Risk Manag Healthc Policy</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>117</fpage>
            <page-range>117-125</page-range>
            <pub-id pub-id-type="pmid">30197544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>La&#x000e4;s</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Naidoo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Oral anticoagulants and atrial fibrillation: A South African perspective.</article-title>
            <source>S Afr Med J</source>
            <year>2018</year>
            <month>Jul</month>
            <day>25</day>
            <volume>108</volume>
            <issue>8</issue>
            <fpage>640</fpage>
            <page-range>640-646</page-range>
            <pub-id pub-id-type="pmid">30182879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bai</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Madan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alshahrani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Volgman</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Sex Differences in Atrial Fibrillation-Update on Risk Assessment, Treatment, and Long-Term Risk.</article-title>
            <source>Curr Treat Options Cardiovasc Med</source>
            <year>2018</year>
            <month>Aug</month>
            <day>27</day>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>79</fpage>
            <pub-id pub-id-type="pmid">30146677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brieger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amerena</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Attia</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bajorek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Connell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haqqani</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Hendriks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hespe</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Worthington</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zwar</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018.</article-title>
            <source>Med J Aust</source>
            <year>2018</year>
            <month>Oct</month>
            <day>15</day>
            <volume>209</volume>
            <issue>8</issue>
            <fpage>356</fpage>
            <page-range>356-362</page-range>
            <pub-id pub-id-type="pmid">30067936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pharithi</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Ranganathan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Egom</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McAuliffe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vaughan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coughlan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morrissey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McHugh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.</article-title>
            <source>Ir J Med Sci</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>188</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-108</page-range>
            <pub-id pub-id-type="pmid">29860595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17962.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dan</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Iliodromitis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Scherr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mar&#x000ed;n</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lenarczyk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Estner</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Kostkiewicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dagres</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GYH</given-names>
              </name>
            </person-group>
            <article-title>Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey.</article-title>
            <source>Europace</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>1382</fpage>
            <page-range>1382-1387</page-range>
            <pub-id pub-id-type="pmid">29893840</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
